Current therapies for non-Hodgkin lymphoma commonly include CD20 mAb to deplete tumor cells. However, the response is not durable in a substantial proportion of patients. Herein, we report our studies in mice testing the hypothesis that heterogeneity in endogenous tissue CD20 + B cell depletion influences in vivo lymphoma therapy. Using highly effective CD20 mAbs that efficiently deplete endogenous mature B cells and homologous CD20 + primary lymphoma cells through monocyte-and antibody-dependent mechanisms, we found that lymphoma depletion and survival were reduced when endogenous host B cells were not depleted, particularly a rare IL-10-producing B cell subset (B10 cells) known to regulate inflammation and autoimmunity. Even small numbers of adoptively transferred B10 cells dramatically suppressed CD20 mAb-mediated lymphoma depletion by inhibiting mAb-mediated monocyte activation and effector function through IL-10-dependent mechanisms. However, the activation of innate effector cells using a TLR3 agonist that did not activate B10 cells overcame the negative regulatory effects of endogenous B10 cells and enhanced lymphoma depletion during CD20 immunotherapy in vivo. Thus, we conclude that endogenous B10 cells are potent negative regulators of innate immunity, with even small numbers of residual B10 cells able to inhibit lymphoma depletion by CD20 mAbs. Consequently, B10 cell removal could provide a way to optimize CD20 mAb-mediated clearance of malignant B cells in patients with non-Hodgkin lymphoma.
Introduction
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignancies that represents approximately 4% of all cancers. More than 90% of NHLs have a B cell phenotype, and almost all express cell surface CD20 (1) . A chimeric CD20 mAb, rituximab, was the first mAb to be approved for clinical use in NHL immunotherapy (2) . Rituximab is given either alone or in combination with chemotherapy for the treatment of both indolent and aggressive NHL (3) . Although CD20 mAb has become a standard therapy for NHL, less than 50% of patients have a durable response (4) . While rituximab is effective in depleting the vast majority of circulating B cells, these only represent approximately 2% of all B cells. The levels of tissue B cell depletion are variable in both humans and primates (reviewed in ref. 5 ). In one study, for example, more than 10% of oncology patients given rituximab at high concentrations did not respond, with circulating B cells remaining in some patients (6) . Even among patients exhibiting some blood B cell depletion, there can be considerable heterogeneity. Similar results have been obtained in lupus patients, highlighting the potential variability of B cell depletion by rituximab in the treatment of autoimmune disease (7) . Other than for Fc receptor polymorphisms in some patients (8, 9) , molecular explanations for variable responses remain unknown (4) , but are undoubtedly due to inconsistency in the strength of effector mechanisms among patients and molecular variability among tumors. The lack of mechanisms that explain patient variability has been a barrier to advances in the field. The current study therefore examined the relative influence of remnant endogenous B cells as positive or negative regulators of lymphoma depletion following CD20 immunotherapy.
In addition to antibody production, B cells can have both positive and negative regulatory activities (10) . B cells can function as costimulatory antigen-presenting cells to induce CD4 + T cell activation and differentiation, which can contribute to autoimmune disease (11) . In contrast, specific B cell subsets can also negatively regulate immune responses in mice, validating the existence of regulatory B cells (12) (13) (14) (15) (16) . A subset of regulatory B cells, termed B10 cells, was recently found to limit T cell-dependent inflammation and autoimmune disease through the production of IL-10 (17, 18), a potent regulatory cytokine (19) . Although regulatory B10 cells only represent 1%-4% of spleen B cells, they negatively regulate the severity of autoimmune disease and inflammation (17, 18) . Human B10 cells and regulatory B cells that parallel their mouse counterparts have also been described (20, 21) . Given the positive and negative regulatory properties of endogenous B cells and B10 cells, their incomplete in vivo depletion during CD20 mAb treatment may directly influence lymphoma immunotherapy and contribute to patient variability.
Whether endogenous B cells can influence in vivo lymphoma therapy was examined using WT and CD20-deficient (Cd20 -/-) mice, since mechanistic studies are not possible in humans. B cell and immune system development are normal in Cd20 -/-mice (22) . Highly effective CD20 mAbs can efficiently deplete endogenous mature B cells and homologous CD20 + primary lymphoma cells in WT mice with otherwise normal immunity through monocyte-and antibody-dependent mechanisms (23, 24) . In this study, however, endogenous B cells in Cd20 -/-mice or IL-10 production by small numbers of adoptively transferred B10 cells inhibited lymphoma clearance and reduced survival in mice given CD20 mAbs. Mouse B10 cell inhibition of lymphoma clearance by CD20 mAbs was explained by their ability to negatively regulate monocyte activation, a property shared with human B10 cells (20) . Therefore, B10 cells are potent negative regulators of innate immune responses and their removal is essential for optimal CD20 mAb clearance of malignant B cells in vivo.
Results

Endogenous B cells inhibit lymphoma immunotherapy.
The role of endogenous B cells during lymphoma immunotherapy was examined using mouse anti-mouse CD20 mAbs (MB20-11) and mouse CD20-expressing primary Burkitt-like lymphoma cells isolated from a syngeneic Eμ-cMycTG +/-mouse (23) . A single dose of MB20-11, but not control mAbs (250 μg/mouse), depletes more than 95% of mature B cells in lymphoid tissues of WT mice after 7 days, with the effect lasting up to 8 weeks (5, (23) (24) (25) (26) (27) (28) (29) . WT mice given 10 5 BL3750 cells on day 0 developed detectable tumors at the site of injection by 12-19 days, with a 31-day median survival (range 27-39; Figure 1 , A and B). CD20 mAbs given to WT mice 1 day after BL3750 cell transfers had a significant therapeutic effect on tumor growth, with 89% of mice remaining disease free for 60 days or longer (P < 0.0001). Transplantation of 10 6 BL3750 cells resulted in death of all control mAb-treated mice (median 25 days, range [21] [22] [23] [24] [25] [26] [27] [28] [29] . CD20 mAb treatment on days 1 and 7 delayed tumor growth and extended median survival by 36% (34 days, P < 0.0001). In contrast, CD20 mAb treatment of Cd20 -/-mice did not deplete endogenous B cells and only induced survival in 50% of mice given 10 5 CD20 + BL3750 cells (P < 0.001). Tumor growth and survival were equivalent in Cd20 -/-mice given 10 6 BL3750 cells regardless of CD20 (median 28 days, range [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] or control (median 31 days, range 23-36) mAb treatment. Thus, the antitumor effects of CD20 mAbs were observed in WT mice, but not in Cd20 -/-mice.
The differences in tumor immunotherapy between WT and Cd20 -/-mice did not reflect variability in BL3750 tumor growth or CD20 mAb effects in vivo. There was prolonged survival of Cd20 -/-mice relative to WT littermates given BL3750 cells ( Figure  1C ), but this is readily explained by immune responses generated against CD20 present on BL3750 cells (22) . However, antitumor, anti-idiotype, or anti-CD20 mAb antibodies were not detectable in Cd20 -/-mice with or without CD20 mAb treatment (data not shown). Furthermore, CD20 mAbs readily depleted more than 95% of tissue B cells in WT mice, regardless of whether they had been given BL3750 cells 1 day before mAb treatment ( Figure 2A ). CD20 mAbs also depleted CFSE-labeled WT B cells equally in WT and Cd20 -/-recipients ( Figure 2B ). Thus, the persistence of endogenous B cells in Cd20 -/-mice significantly inhibited the antitumor effects of CD20 mAbs that were observed in WT mice.
Small numbers of B10 cells inhibit CD20 immunotherapy. Since IL-10-competent B10 cells regulate inflammation and immune responses, their role in CD20 immunotherapy was evaluated. B10 cells are identified by their ability to express cytoplasmic IL-10 following 5 hours of in vitro stimulation with LPS, PMA, and ionomycin, with monensin included in the cultures to block IL-10 secretion (30, 31) . Negative controls for IL-10 staining included isotypematched control mAbs and B cells from IL-10-deficient (Il10 -/-) mice. Spleen B10 cell frequencies and numbers were equivalent in WT and Cd20 -/-mice, but CD20 mAb treatment only depleted B10 cells from WT mice (>95%; Figure 3A) . Remarkably, B10 cell
Figure 1
Endogenous B cells inhibit lymphoma depletion by CD20 mAbs in vivo. (A) Representative dorsal tumors resected from control (Ctrl) or CD20 mAb-treated WT or Cd20 -/-mice 16 days after receiving 10 6 BL3750 cells. Line graphs indicate tumor volumes for mice given CD20 (black circles) or control (white circles) mAbs (250 μg/mouse) on days 1 and 7 (arrowheads) following the transfer of 10 6 BL3750 cells. Values represent mean tumor volumes observed in 3-6 mice for each group from 2 independent experiments. (B) Survival of WT or Cd20 -/-mice given 10 5 (left panels) or 10 6 (right panels) BL3750 cells on day 0, with CD20 (black circles) or control (white circles) mAbs given on day 1 or days 1 and 7 (arrowheads) in 3 or more independent experiments. Significant cumulative survival differences between groups treated with CD20 versus control mAbs are indicated. All mice that survived more than 90 or 50 days (as shown) remained disease free for 6 or more months. (C) Survival of WT and Cd20 -/-mice given 10 5 or 10 6 BL3750 cells on day 0. Significant cumulative survival differences between WT and Cd20 -/-mice are indicated. Data represent mean ± SEM.
frequencies also expanded 2-fold in tumor-bearing WT ( Figure 3B ) and Cd20 -/-mice (data not shown) by day 28. However, the relative frequency of spleen B10 cells decreased significantly as BL3750 cells displaced spleen lymphocytes, which argues that B10 cells were not required for lymphoma progression.
To determine whether B10 cells inhibited the antitumor effects of CD20 mAbs in vivo, CD1d hi CD5 + B cells that are enriched for B10 cells and progenitor B10 (B10pro) cells or conventional non-CD1d hi CD5 + B cells were purified from Cd20 -/-mice (Figure 3C ) and adoptively transferred into WT mice as described (17, 18) . B10 cells represented 9%-11% of the spleen CD1d hi CD5 + B cell subset, while B10 cells represented less than 1% of nonCD1d hi CD5 + B cells. Therefore, the adoptive transfer of 2 × 10 6 CD1d hi CD5 + B cells included approximately 2 × 10 5 IL-10-competent B10 cells. Recipient mice were given 10 6 BL3750 cells 1 day later (day 0), followed by CD20 or control mAb treatment. CD20 mAb treatment delayed tumor growth and prolonged survival in WT mice (median 34 days, range 21-39; P < 0.0001; Figure 4 ). However, the adoptive transfer of Cd20 -/-CD1d hi CD5 + B cells eliminated the therapeutic benefit of CD20 mAbs and reduced survival to levels observed in control mAb-treated mice (median 24 days, range [21] [22] [23] [24] [25] [26] . The adoptive transfer of Cd20 -/-CD1d lo CD5 -B cells was without effect.
Whether B10 cell IL-10 production was responsible for eliminating the therapeutic benefit of CD20 mAb treatment was determined using B cells from Il10 -/-Cd20 -/-mice. The adoptive transfer of either CD1d hi CD5 + or CD1d lo CD5 -B cells from Il10 -/-Cd20 -/-mice into WT mice did not affect tumor growth or mouse survival following CD20 mAb treatment (Figure 4 Efficient depletion of WT B cells by CD20 mAbs in Cd20 -/-mice. Cd20 -/-and WT splenocytes were CFSE labeled at different intensities, mixed equally, and transferred into WT or Cd20 -/-recipients before CD20 or control mAb treatment. Spleen and peripheral lymph node lymphocytes were isolated after 3 days and stained for CD19 expression. The gates show CD19 + and CD19 -lymphocytes from WT donors (CFSE hi ) relative to Cd20 -/-donors (CFSE lo ). Bar graphs indicate mean CD20 + to CD20 -cell ratios within the CFSE-labeled CD19 + and CD19 -lymphocyte populations from 2 independent experiments. Data represent mean ± SEM.
B10 cells regulate macrophage activation.
To determine how B10 cells regulate CD20 mAb-induced lymphoma depletion, the relative contributions of innate effector cells to lymphoma and B cell depletion by CD20 mAbs was assessed. CD20 mAbs deplete normal and malignant B cells through IgG Fc receptors (FcγR) (23, 24) . Lymphoma depletion was dependent on monocytes, as their clodronate-induced depletion from tumor-bearing mice (WT/ Clod) eliminated the therapeutic benefit of CD20 mAbs ( Figure  5B ). Likewise, macrophage depletion significantly reduced blood and spleen B cell clearance over a range of CD20 mAb concentrations ( Figure 5C ). Lymphoma depletion did not require endogenous B or T cells, as CD20 mAb treatment significantly prolonged the survival of Rag1 -/-mice given BL3750 cells ( Figure 5B ). Since monocytes, neutrophils, and NK cells are required for host defense, their relative contributions to normal B cell depletion by CD20 mAbs was compared in mice without tumors. Mcl1 -/-mice have 80%-86% reductions in blood and spleen neutrophils, but have normal macrophages (32) . Gfi1 -/-mice lack phenotypically mature neutrophils, while morphologically normal monocytes are present in normal numbers (33) . Splenic B220 + B cells from WT, Mcl1 -/-, and Gfi1 -/-mice expressed cell-surface CD20 at identical levels (data not shown). NK1.1 mAb treatment reduced circulating NK cells by 93% ± 2%, as determined by DX5 mAb staining (data not shown). Nonetheless, CD20 mAb treatment depleted normal numbers of blood and spleen B cells in Mcl1 -/-, Gfi1 -/-, and NK cell-depleted mice after 7 days. Thus, CD20 mAb-induced lymphoma and B cell depletion were macrophage dependent.
Since monocytes express the IL-10 receptor at high levels (19) , the effect of adoptively transferred B10 cells on monocyte activation was examined in vivo. Spleen CD1d hi CD5 + B cells were purified from Cd20 -/-mice and transferred into WT mice that were later given BL3750 cells followed by CD20 mAbs 1 day later. Forty-eight hours after CD20 mAb treatment, activation-induced upregulation of major histocompatibility class II molecules and CD86 expression were significantly reduced on splenic CD11b + cells from mice given Cd20 -/-CD1d hi CD5 + B cells ( Figure 6A ). LPS-induced nitric oxide and TNF-α production were also significantly reduced when bone marrow CD11b + cells or peritoneal macrophages were cocultured with CD1d hi CD5 + B cells, but were significantly increased when the cells were cocultured with CD1d lo CD5 -B cells ( Figure  6 , B-D). CD1d hi CD5 + B cell regulation of nitric oxide and TNF-α production was completely IL-10 dependent ( Figure 6 , B and D). Thus, CD1d hi CD5 + B cells can significantly reduce monocyte activation in vivo and in vitro.
TLR activation enhances CD20 mAb efficacy in vivo. Since monocyte activation may bypass B10 cell-negative regulation in WT mice, the ability of TLR stimulation to enhance lymphoma depletion was evaluated. TLR3 (polyinosinic-polycytidylic acid; poly[I:C]), TLR4 (LPS), and TLR9 (CpG) agonists induced significant TNF-α production by bone marrow CD11b + cells ( Figure 7A ) and induced higher FcγRII/III expression levels on spleen macrophages, neutrophils, and NK cells ( Figure 7B ).
Whether TLR agonists could also augment B cell depletion in vivo was determined in mice given limited amounts of MB20-11 CD20 mAbs, with peritoneal cavity B cells enumerated 7 days later. Peritoneal cavity B cells are normally refractory to CD20 mAb-induced depletion due to the low number of endogenous monocytes (5). However, giving mice TLR agonists significantly enhanced the removal of peritoneal B cells in a CD20 mAb dosedependent manner ( Figure 7 , C and D). These TLR agonists also significantly induced B cell depletion in response to a CD20 mAb (MB20-1, IgG1) that is less efficient at FcγR engagement than MB20-11 mAbs (24) . CD20 mAb treatment alone reduced peritoneal B2 cell numbers significantly, while peritoneal B1a and B1b B cells were less affected ( Figure 7D ). However, 98%, 82%-93%, and 94%-95% of peritoneal B2, B1a, and B1b cells, respectively, were depleted by CD20 mAbs in mice given TLR agonists. The ability of CpG to enhance peritoneal B cell depletion by CD20 mAbs was significantly reduced by MyD88 deficiency (Figure 7E ), which reduces TLR4 and TLR9 signaling (34) . Thus, TLR signaling significantly enhanced CD20 mAb-induced B cell depletion under conditions in which B cell clearance was limited.
Poly(I:C) enhances CD20 mAb-induced lymphoma depletion. The ability of TLR activation to augment lymphoma depletion was determined in mice given BL3750 cells on day 0 followed by control mAbs plus TLR agonists on days 1, 7, 14, and 21. Only poly(I:C) significantly enhanced mouse survival (median 33 days; Figure 8A ). The ability of TLR agonists to augment low-dose CD20 mAb (10 μg) effectiveness in vivo was also examined. The median survival of mice given lymphomas and CD20 mAbs alone was 33 days (range [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . The median survival of mice given CD20 mAbs along with LPS (42 days, P < 0.05) or CpG (37 days) was increased. However, the median survival of mice given CD20 mAbs along with poly(I:C) was dramatically increased (>60 days, P < 0.001), with this treatment preventing tumors in 62% of mice for up to 6 months. Half of mice given BL3750 cells along with low-dose CD20 mAbs and 50-500 μg of poly(I:C) weekly for 4 weeks survived, while none of the control or CD20 mAb-treated mice survived (P < 0.01; Figure 8B ). The combination of low-dose CD20 mAbs plus poly(I:C) also significantly reduced circulating leukocyte counts (P < 0.01) and delayed tumor growth (P < 0.01) when compared with CD20 mAbs alone or control mAbs plus poly(I:C) ( B cell IL-10 production inhibits lymphoma depletion by CD20 mAbs in vivo. CD1d hi CD5 + B cells inhibit lymphoma depletion by CD20 mAbs through IL-10 production. B cell subsets purified from Cd20 -/-or Il10 -/-Cd20 -/-mice were transferred into WT recipients (2 × 10 6 / mouse) 1 day before the mice were given 10 6 BL3750 tumor cells on day 0. CD20 or control mAbs (250 μg) were given on days 1 and 7 (arrowheads). Representative dorsal tumors were resected from mice on day 16. Tumor volumes and cumulative mouse survival were quantified after tumor challenge and control (white circles), CD20 mAb (black circles), CD20 mAb plus CD1d hi CD5 + B cell (squares), or CD20 mAb plus non-CD1d hi CD5 + B cell (triangles) treatments. Results represent pooled data from 4 independent experiments. Significant cumulative survival differences between groups given CD1d hi CD5 + or non-CD1d hi CD5 + B cells are shown. All mice that survived more than 50 days remained disease free for 6 or more months. Data represent mean ± SEM.
and TRIF-dependent pathways, since it was unable to augment the phagocytic capacity of macrophages isolated from Tlr3 -/-or Trif -/-mice ( Figure 9B ). Spleen B cells and BL3750 cells expressed modest if any TLR3 transcripts, while TLR4 and TLR9 transcripts were readily identified ( Figure 9, C and D) . Consistent with this, spleen B cells proliferated significantly in response to LPS and CpG stimulation, but not poly(I:C) (P < 0.05; Figure 9E ). Culturing mouse spleen B cells or human blood mononuclear cells with LPS or CpG induced significant numbers of B10pro cells to mature into IL-10-secreting B10 cells, while poly(I:C) was without effect (Figure 9 , F and G). These TLR agonists or IL-10 did not induce BL3750 cells to express IL-10 ( Figure 9 , F-H) or significantly affect BL3750 cell proliferation, survival, and CD20 expression (Supplemental Figure 2B ). Thus, poly(I:C) enhanced antibody-dependent phagocytosis, while not inducing B10pro cell maturation, B10 cell IL-10 secretion, or B cell proliferation.
Poly(I:C) overcomes the inhibitory effect of endogenous B cells on CD20 immunotherapy.
To determine whether poly(I:C) circumvents the negative regulatory effects of B10 cells, Cd20 -/-mice were given BL3750 cells and subsequently treated with CD20 mAbs plus poly(I:C). Cd20 -/-mice given either poly(I:C) or CD20 mAbs alone developed detectable tumors by 14-25 days, with a median survival of 32 and 35 days, respectively ( Figure 10A ). CD20 mAb plus poly(I:C) treatment significantly delayed tumor growth and extended median survival by 29% relative to CD20 mAbs alone (45 days, P < 0.05). Thus, poly(I:C) treatment significantly reduced the inhibitory effect of endogenous B10 cells on CD20 immunotherapy.
CD19 mAbs also deplete B cells in human CD19 transgenic mice through monocyte-and FcγR-dependent mechanisms (35, 36) . Therefore, the therapeutic benefit of poly(I:C) was also tested using mouse anti-mouse CD19 mAbs and BL3750 cells, which express cell surface CD19 (23) . CD19 mAbs given 1 day after transfer of BL3750 cells significantly prolonged mouse survival (P < 0.05; Figure 10B) . Remarkably, 75% of the mice treated with poly(I:C) plus CD19 mAbs remained tumor free until the experiment was terminated at 180 days.
Whether poly(I:C) treatment could also overcome lymphoma resistance to CD20 mAb treatment was determined using a CD20 mAb-resistant CD20 + subclone of BL3750 cells. High-dose CD20 mAb treatment given 1 day after the transfer of BL3750-6 cells had no therapeutic benefit in WT mice, with median survival of 33 days in control or CD20 mAb-treated mice ( Figure 10C ), even though BL3750 and BL3750-6 cells expressed CD20 at similar densities ( Figure 10D ). Nonetheless, CD20 mAb plus poly(I:C) treatment significantly prolonged survival when compared with CD20 mAb treatment alone (15% increase; Figure 10C ). Thereby, poly(I:C) treatment significantly enhanced CD20 or CD19 mAb-induced lymphoma depletion in either WT or Cd20 -/-mice.
Discussion
Endogenous B10 cells were found to be potent negative regulators of lymphoma depletion during CD20 immunotherapy. While the depletion of tissue B10 cells along with conventional B cells prolonged survival in WT mice given primary CD20 + lymphoma cells and CD20 mAbs, the presence of even small numbers of CD1d hi CD5 + B10 cells, but not conventional B cells, significantly inhibited lymphoma depletion through IL-10-dependent mechanisms (Figures 1-4) . The absence of tumor clearance in Cd20 -/-mice was not expected, since circulating CD20 mAb levels persist longer in Cd20 -/-mice than in WT littermates (5) and Cd20 -/-mice can develop immune responses to CD20 + tumors (25) . Tissue B10 cell numbers were also increased 2-fold with lymphoma progression ( Figure 3B ), which mimics increased B10 cell numbers during inflammation and autoimmunity (17, 18) . As a consequence, the incomplete or delayed depletion of tissue B10 cells may significantly reduce the effectiveness of CD20 immunotherapy in some lymphoma patients, as also occurs with Fc receptor polymorphisms. In support of this, endogenous B cell depletion by CD20 mAbs is significantly reduced in NOD mice that also have elevated B10 cell numbers (29, 30) . While our most potent anti-mouse CD20 mAb depletes most mature B cells efficiently in C57BL/6 mouse tissues, this may not be the case for current human CD20 therapies (6, 7). Thus, the effective removal or functional inactivation of tissue B10 cells may significantly augment lymphoma depletion during human CD20 immunotherapy.
That mouse and human B10 cell IL-10 production regulate macrophage activation in vivo and in vitro (Figure 6 and ref. 20) provides a mechanistic explanation for B10 cell regulatory effects during lymphoma immunotherapy. Macrophages serve as the primary in vivo mediators of CD20 mAb-dependent lymphoma depletion in mice ( Figure 5 and ref. 23 ). Monocytes are also critical for rituximab clearance of human lymphoma xenografts in nude mice (37) . Therefore, inducing macrophage activation but not B10 cell IL-10 production through the provision of poly(I:C) along with CD20 mAbs significantly enhanced lymphoma depletion (Figures 8 and 10 ). Poly(I:C) activates human and mouse monocytes/macrophages through its intracellular TLR3 receptor-and TRIF-dependent signaling pathways (38) , while B cell TLR3 expression and its functional effects on B cells were modest (Figure 9 , C-G, and refs. 39, 40). Poly(I:C), LPS, and CpG enhanced innate immune cell FcγR expression and induced their production of TNF-α ( Figure 7, A and B) and IFN-γ (data not shown) in vitro, but cell-surface TLR4 and TLR9 are broadly expressed by most leukocytes (41) . However, TLR4 and TLR9 agonists also induced B10 cell expansion and IL-10 production, which may explain in part why LPS and CpG only modestly enhanced CD20 mAb-induced lymphoma depletion. The varied effects of these 3 TLR agonists on antitumor therapy may also have involved their differential effects on regulatory or effector T cells as well as the effects of B10 cells on immune cells other than macrophages, but did not appear to result from direct effects on BL3750 tumor cells (Figure 9 , F-H, and Supplemental Figure 2) . Thus, selective monocyte but not B10 cell activation may provide new pathways for augmenting innate immune effector functions during CD19 and CD20 mAb and other FcγR-dependent therapies.
The current studies provide new understanding of the factors and molecular mechanisms regulating the efficacy of CD20 immunotherapy in vivo, with new findings that may be translatable into therapeutic use. Augmenting CD20 mAb effects through TLR3 agonists may be particularly advantageous when B10 cell or tumor cell numbers are significant, when tumors express CD20 at low densities, when host FcγR expression or function is compromised, or when monocyte numbers or function is reduced. Although poly(I:C) is not used clinically because of its demonstrated toxicities in mice and humans (42, 43) , poly(I:C)-like agents are available for therapeutic use. As examples, poly-ICLC (Hiltonol), poly I: poly C 12 U (Ampligen, Oragen, atvogen), and poly I-mercapto poly C (polyI:MPC) have well-characterized side effects and safety profiles (44) (45) (46) (47) (48) (49) . Rituximab-induced cellular cytotoxicity against tumor targets is improved significantly by the addition of poly I: poly C 12 U to in vitro blood cell cultures (50) . Combining poly(I:C)- , and B2 (CD5 -CD11b -IgM hi B220 hi ) cell numbers in mice 7 days after CD20 (MB20-11, black bars) or control (white bars) mAb (25 μg) treatment plus PBS, poly(I:C), LPS, or CpG (≥3 mice per value). (E) CpG does not augment peritoneal cavity B cell depletion by CD20 mAbs (MB20-11, 25 μg) in Myd88 -/-mice. Percentages represent mean B220 + cell frequencies 7 days after CD20 mAb treatment relative to control mAb-treated littermates (≥3 mice per value). CD19 + B cells from WT and Myd88 -/-mice express similar cell-surface CD20 densities as assessed over a range of CD20 mAb concentrations relative to control mAbs (10 μg/ml) binding. (C-E) Significant differences between sample means are indicated. *P < 0.05; **P < 0.01. Results represent 3-4 independent experiments. Data represent mean ± SEM.
related drugs with CD20 mAbs may also provide new therapeutic approaches for chronic lymphocytic leukemia and other B cell malignancies that are intrinsically resistant to CD20 mAb therapy (51, 52) . Therefore, B10 cell depletion or B10 cell-or TLR3-directed drugs may represent powerful therapeutic approaches for enhancing CD19, CD20, and other mAb treatments for lymphoma and potentially other cancers.
LPS and CpG treatments modestly improved the outcome of CD20 immunotherapy ( Figure 8A ). However, CpG treatment does enhance the efficacy of an anti-IgM idiotype mAb against murine B cell lymphoma by enhancing NK cell and granulocyte antibodydependent killing in vitro (53, 54) . Furthermore, CpG treatment is reported to increase CD20 expression by malignant B cells (55) . Based on these findings, a phase I clinical trial for CpG in combination with rituximab treatment weekly for 4-20 weeks was carried out in patients with relapsed/refractory CD20 + B cell NHL (56, 57) . Combined CpG and rituximab treatments were well tolerated and without major toxicities. Nevertheless, the use of TLR9 agonists may be complicated, since B cell-derived lymphomas and normal B cells express TLR9 (Figure 9, C and D, and ref. 58) . Furthermore, repeated CpG administration has negative consequences in mice, including severely altered morphology and functionality of lymphoid organs, multifocal liver necrosis, and hemorrhagic ascites (59) . In contrast, repetitive poly(I:C) challenge is not immunotoxic or hepatotoxic in mice (59) . Blocking B10 cell function by providing an IL-10-neutralizing antibody systemically (17) is unlikely to prove effective long-term, since IL-10 is an important regulatory cytokine that is produced by a large number of hematopoietic and nonhematopoietic cells as part of multiple diverse regulatory circuits (19) . Moreover, IL-10-deficient mice develop multiple manifestations of heightened cellular and humoral immunity, which eventually lead to systemic inflammation and autoimmunity. Thus, poly(I:C)-like TLR agonists may be preferred agents for enhancing CD20 mAb efficacy in vivo.
These studies demonstrate that optimal lymphoma depletion during immunotherapy involves at least 2 mechanisms: direct CD20 mAb targeting of tumor cells for depletion by monocytes and enhanced tumor depletion by the removal of endogenous B10 cells. B10 cells may also negatively regulate other tumor-specific immune responses. For example, CD20 mAb removal of endogenous B10 cell-negative regulation may explain the recent observation that B cell depletion prior to adoptive immunotherapy with T cells expressing CD20-specific chimeric T cell receptors facilitates the eradication of leukemia in immunocompetent mice (60) . Preferential B10 cell depletion in mice also significantly enhances both cellular and humoral immune responses (61, 62) . Enhanced immunity and resistance to diverse syngeneic tumors has also been reported in congenitally B cell-deficient μMT mice (63) (64) (65) . The significant role for B10 cells in mAb-mediated tumor depletion provides an additional explanation for these previous studies and identifies an
Figure 8
Poly(I:C), but not LPS or CpG, enhances lymphoma depletion by CD20 mAbs. (A) Poly(I:C) enhances CD20 mAb-induced lymphoma depletion. Control or CD20 mAbs (10 μg) were given concurrently with PBS (white circles), poly(I:C) (squares), LPS (black circles), or CpG (triangles) on days 1, 7, 14, and 21 following 10 5 BL3750 cell transfers. Significant cumulative survival differences between groups are indicated. B cell depletion kinetics for 10 μg MB20-11 mAbs have been described (24, 29) unanticipated mechanism through which human CD20-directed therapies can be optimized for lymphoma treatment.
Methods
Mice. Cd20 -/-mice were as described (22) . C57BL/6 mice were from NCIFrederick Laboratory. Il10 -/-(B6.129P2-Il10 tmlCgn /J) and Rag1 -/-(B6.129S7-Rag1 tm1Mom /J) mice were from the Jackson Laboratory. Mcl1 -/-mice were as described (32) . Gfi1 -/-mice (33) were provided by H. Hock (Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA). TLR3 -/-(B6;129S1-Tlr3 tm1Flv /J) and TRIF -/-(C57BL/6J-Ticam1 Lps2 /J) mice were from the Jackson Laboratory. Myd88 -/-mice (66) were provided by S. Akira (Osaka University, Osaka, Japan). Mice were housed in a specific pathogen-free barrier facility and first used at 6-10 weeks of age.
Immunofluorescence analysis. CD20 and CD22 expression were visualized using biotin-conjugated CD20 (MB20-11) (22) nologies), or poly(I:C) (Invivogen) for 48 hours at 37°C in a tissue culture incubator with 5% CO2 atmosphere, with the addition of monensin, PMA, and ionomycin for the last 5 hours of culture. For TNF-α detection, bone marrow cells were resuspended (2 × 10 6 cells/ml) in complete medium with brefeldin A (1 μl; Biolegend) and TLR agonists (25 μg/ml) for 4 hours. Before cell-surface staining, Fc receptors were blocked using Fc receptor mAbs (2.4G2; BD Biosciences), and dead cells were labeled using a LIVE/ DEAD Fixable Violet Dead Cell Stain Kit (Invitrogen-Molecular Probes). Stained cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions and stained with anti-IL-10 or anti-TNF-α mAbs. Isotype-matched mAbs or splenocytes from Il10 -/-mice served as negative controls for IL-10 staining to demonstrate specificity and to establish background IL-10 staining levels. Isotype-matched mAbs or cells cultured with brefeldin A only served as negative controls for TNF-α staining. Human blood was obtained with informed consent according to protocols approved by the Institutional Review Board of Duke University.
CD20 immunotherapy and TLR agonist treatments. Sterile mouse anti-mouse CD20 mAbs MB20-11 (IgG2c) and MB20-1 (IgG1), and unreactive mouse control IgG2a and IgG1 mAbs were as described (24) . In some experiments, mice were treated with anti-NK1.1 mAbs (100 μg) on day -4 and day 3 for NK cell depletion. Antibodies were purified by protein A affinity chromatography (Amersham) and determined to be endotoxin free (Limulus Amoebocyte Lysate assay, sensitivity of 0.06 EU/ml; Cambrex Bio Science). Macrophage deficiency was generated by tail-vein injections of clodronate-encapsulated liposomes (Sigma-Aldrich) or control PBS-encapsulated liposomes (69) in 0.2 ml given on day -1 and 0.1 ml given on days 2, 5, and 9 ( Figure 5B ) or 0.2 ml given on days -2, 1, and 4 (Figure 5C ). For TLR agonist treatment, mice were given poly(I:C) (150 μg; Sigma-Aldrich; InvivoGen), LPS (10 μg; Sigma-Aldrich), or CpG ODN 1668 (5′-tccATGACGTTCCTGAtgcT-3′ [bases in lower case are phosphorothioate], 50 μg; Integrated DNA Technologies) i.p. concurrent with PBS or mAbs. For assessing WT B cell depletion in Cd20 -/-mouse studies, splenocytes from Cd20 -/-and C57BL/6 mice were differentially labeled with 0.5 and 5.0 μM CFSE Vybrant CFDA SE Fluorescent Dye (Invitrogen), respectively, as described (5). C57BL/6 and Cd20 -/-splenocytes were mixed in equal numbers and given to Cd20 -/-or C57BL/6 mice (10 8 , i.v.) 1 day before mAb (250 μg) treatment, with CFSE-labeled cell frequencies determined 3 days later.
B cell adoptive transfer experiments. Naive Cd20 -/-or Il10 -/-Cd20 -/-mice were used as B cell donors. Splenic B cells were first enriched using CD193 mAb-coated microbeads (Miltenyi Biotec) according to the manufacturer's instructions. In addition, CD1d hi CD5 + and CD1d lo CD5 -B cells were isolated using a FACSVantage SE flow cytometer (BD) with purities of 95%-98%. After purification, 2 × 10 6 cells were immediately transferred i.v. into C57BL/6 mice. In some experiments, we used B10 cell donor mice that had survived for 30-45 days after tumor challenge (10 5 BL3750 cells on day 0) and CD20 mAb treatment (250 μg on day 1). Similar results were obtained when the donor B cells were isolated from naive mice or mice that had survived BL3750 challenge, so all results were pooled.
TLR transcript expression. Total RNA was isolated from whole spleen cells, splenic B cells purified using B220-mAb coated microbeads, and BL3750 cells using TRIzol reagent (Invitrogen). Random hexamer primers (Promega) and Superscript II RNase H Reverse Transcriptase (Invitrogen) were used to generate cDNA. PCR primer pairs were used to amplify TLR transcripts as described (70) . Relative TLR transcript levels were also quantified by GeneChip analysis (Affymetrix). Chip transcript levels were normalized to the 50th percentile using GeneSpring software (Agilent Technologies).
Cell proliferation and IL-10 secretion. Purified splenic B cells or BL3750 cells were labeled with CFSE Vybrant CFDA SE Fluorescent Dye (5 μM; Invitrogen). Labeled B cells were then cultured in medium with LPS (25 μg/ml), CpG (25 μg/ml), poly(I:C) (25 μg/ml), or recombinant mouse IL-10 (10 ng/ml; Biolegend) for 72 hours, with cell division assessed by (A-C) Mice were given BL3750 cells 1 day before isotype control mAb (white circles, 250 μg), CD20 (250 μg), or CD19 (100 μg) mAb (black circles) treatments. Poly(I:C) (squares, triangles, 150 μg) was either given alone or with mAbs on days 1, 7, 14, and 21 (arrowheads). Significant cumulative survival differences between groups treated with mAbs plus poly(I:C) versus CD20/CD19 mAb alone and poly(I:C) alone are indicated. All mice that survived more than 60 days remained disease free for 6 or more months. (D) BL3750 and BL3750-6 cell-surface CD20, IgM, CD19, and CD22 expression (shaded histogram). Control mAb background staining is shown (thin line), with similar results from 3 or more experiments. Data represent mean ± SEM. flow cytometry. For IL-10 measurements, purified B cells or BL3750 cells (4 × 10 5 ) were cultured in 0.2 ml of complete medium with TLR agonists in 96-well flat-bottom tissue culture plates. Culture supernatant fluid IL-10 concentrations were quantified using IL-10 OptEIA ELISA kits (BD Biosciences -Pharmingen) following the manufacturer's protocols. All assays were carried out using triplicate samples.
In vitro monocyte assays. Mouse splenic CD1d hi CD5 + or CD1d lo CD5 -B cells were purified by cell sorting and cultured with LPS (10 μg/ml) for 24 hours. Bone marrow CD11b + cells (1 × 10 6 /ml) were purified using CD11b microbeads (Miltenyi Biotec) and cultured alone or with LPS-stimulated CD1d hi CD5 + or CD1d lo CD5 -B cells (1 × 10 6 /ml) for 24 hours. Brefeldin A and LPS (1 μg/ml) were added during the final 4 hours of culture. Relative cytoplasmic TNF-α production by CD11b + cells was assessed by immunofluorescence staining. For TNF-α secretion, peritoneal macrophages from thioglycollate-treated mice were isolated by adherence to plastic with more than 85% purity, as determined by immunofluorescence F4/80 + staining, and cultured alone or with LPS-stimulated CD1d hi CD5 + or CD1d lo CD5 -B cells (1 × 10 6 /ml) for 48 hours, with LPS (1 μg/ml) added during the final 18 hours of culture. Tissue culture supernatant fluid TNF-α concentrations were quantified using TNF-α OptEIA ELISA kits (BD Biosciences -Pharmingen). To assess nitric oxide production, supernatant fluid was obtained from cells that were cocultured for 48 hours, with LPS (1 μg/ml) added during the final 18 hours of culture. Nitrite formed from the spontaneous oxidation of nitric oxide was quantified for duplicate samples using a Griess Reagent Kit (Invitrogen-Molecular Probes) following the manufacturer's protocols.
In vitro antibody-dependent phagocytosis assays. Spleen B cells were purified using a B cell isolation kit (Miltenyi Biotec), labeled with CFSE Vybrant CFDA SE Fluorescent Dye (5 μM), and cultured overnight in complete medium. CFSE-labeled B cells were incubated with MB20-11 CD20 mAbs on ice for 1 hour and then washed to remove unbound mAbs. Peritoneal macrophages from thioglycollate-treated mice were isolated by adherence to plastic and cultured for 18 hours with or without TLR agonists (10 or 25 μg/ml) added to the culture medium. Macrophages and B cells were mixed at a 1:1 ratio and cultured for 2.5 hours. The cells were then stained for cell-surface CD11b expression with CFSE + CD11b + double-positive cell frequencies assessed by flow cytometry.
Statistics. Data represent mean ± SEM. Statistical comparisons of differences between sample means used the 2-tailed Student's t test. The generation of Kaplan-Meier cumulative survival plots and log-rank test comparisons of survival used Prism software (version 4.0; GraphPad Software). Cumulative survival differences were based on the survival days shown in each figure, even though some mice remained disease free. Spearman's rank correlation coefficient was used to determine the relationship between 2 variables. P ≤ 0.05 was considered significant.
Study approval. The Duke University Animal Care and Use Committee approved all studies.
